

Singapore stem cell firm initiates for ASX listing

15 July 2015 | News | By BioSpectrum Bureau

Singapore stem cell firm initiates for ASX listing



Singapore: On Q Group, changing its name to StemCell United, a Singapore-based biotechnology company headquartered in Australia, has issued a prospectus for a public offering and listing on the Australian Securities Exchange (ASX) with the Australian Securities and Investment Commission.

The company is announcing a public offer of 23,000,000 new shares at the offer price of \$0.20 per new share. The new shares to be issued will represent approximately 6 percent of the shares on issue on completion of the offer and the entire transaction.

Following completion of the public offer, SCU will acquire the Singapore based company StemCell United (SUP), a biotechnology company which focuses on the extraction, culture, reproduction, and growth of plant stem cells.